Loading clinical trials...
Loading clinical trials...
A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50%
Conditions
Interventions
REGN2810/ipi
REGN2810/chemo/ipi
+1 more
Locations
3
United States
Regeneron Research Site
St. Petersburg, Florida, United States
Regeneron Research Site
Cremona, Italy
Regeneron Research Site
Vilnius, Lithuania
Start Date
July 2, 2018
Primary Completion Date
July 29, 2021
Completion Date
July 29, 2021
Last Updated
November 16, 2022
NCT07431827
NCT06427941
NCT07164313
NCT06253871
NCT07361497
NCT07510724
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions